A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma
A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma. // EMC - Otorinolaringoiatria. – URL: https://www.sciencedirect.com/science/article/pii/S2772610X26000449?dgcid=rss_sd_all
A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma. EMC - Otorinolaringoiatria. https://www.sciencedirect.com/science/article/pii/S2772610X26000449?dgcid=rss_sd_all
“A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma.” EMC - Otorinolaringoiatria.
@article{article5358,
title = {A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma},
journal = {EMC - Otorinolaringoiatria},
url = {https://www.sciencedirect.com/science/article/pii/S2772610X26000449?dgcid=rss_sd_all}
}
Publication date: February 2027 Source: Addictive Behaviors, Volume 185 Author(s): Sean Esteban McCabe, Vita V. McCabe, Kara Dickinson, Thye Peng Ngo, Ty S. Schepis
Publication date: February 2027 Source: Addictive Behaviors, Volume 185 Author(s): Steffani R. Bailey, Jun Hwang, Jennifer A. Lucas, Kristin Lyon-Scott, Miguel Marino, Roopradha Datta, Ana R. Quiñones, Brian Chan, Ximena A. Levander,...
Publication date: February 2027 Source: Addictive Behaviors, Volume 185 Author(s): Marta Narváez-Camargo, Nikola Doubkova, Cinta Mancheño-Velasco, Mia N. Vasquez, Camilo J. Ruggero, Gina Rossi